Streetbeat News

Products Services

INLX

Intellinetics, Inc. (INLX) has announced two recent sales of its IntelliCloud™ Payables Automation System, representing a combined $150,000 in annual SaaS revenue. This reflects the company's growing Payables Automation Solutions practice and provides an upward lift to its annual recurring revenue. The system uses AI and machine learning technologies to streamline general ledger coding, workflows and approvals, data entry, and invoice filing.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:45 pm

INVA

The Global Antibiotic Research & Development Partnership (GARDP) and Innoviva Specialty Therapeutics, a subsidiary of Innoviva, Inc. (NASDAQ:INVA), announced positive results from a Phase 3 trial of zoliflodacin, a first-in-class oral antibiotic for treating uncomplicated gonorrhea. The study met its primary endpoint, demonstrating statistical non-inferiority of microbiological cure at the urogenital site compared to the current standard of care. The success of this study could change how physicians approach gonorrhea infections, offering an oral alternative to injections, improving patient access and compliance, and helping reduce the spread of antibiotic-resistant strains.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:37 pm

EGHT

8x8, Inc. (NASDAQ:EGHT) announced that its AI-powered Intelligent Customer Assistant has enabled organizations to enhance customer service experiences and increase efficiencies in the contact center. Since its launch in March 2023, customers are reporting greater than 70% first-contact resolution rates using the service, and interactions increased over 50% from the previous quarter. The solution integrates with existing contact centers and provides graphical orchestration capabilities, allowing businesses to build scalable, consistent experiences across multiple regions, channels, and languages.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:23 pm

ABCL

PRLD

Prelude Therapeutics Incorporated (NASDAQ:PRLD) and AbCellera (NASDAQ:ABCL) have announced a multi-year partnership to discover, develop, and commercialize potentially first-in-class treatments for cancer patients. The collaboration will combine Prelude's expertise in targeted protein degradation, medicinal chemistry, and clinical development with AbCellera's antibody discovery and development engine to generate novel precision antibody drug conjugates (ADCs).

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:18 pm

RANI

Rani Therapeutics has announced a strategic program prioritization, expansion of manufacturing, and plans to streamline business operations to support near-term value drivers and long-term growth of the RaniPill Technology Platform.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:14 pm

NRIX

Nurix Therapeutics, Inc. (NASDAQ:NRIX) announced that the FDA has placed a partial clinical hold on the Phase 1 NX-2127-001 study evaluating NX-2127 in various B-cell malignancies. The hold follows the company's communication to the FDA of its intention to transition to an improved manufacturing process. Nurix's other drug programs are not affected by the NX-2127 manufacturing process improvement.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:09 pm

RUN

Sunrun (NASDAQ:RUN), a leading provider of clean energy, has launched a new add-on storage offering for California solar customers. The storage allows customers to power through outages, capture additional value from their existing solar installation, and enhance grid reliability. More than 85% of Sunrun's new sales in California included a battery in the most recent quarter. The company's add-on storage offering uses a premium battery product that integrates with customers' existing solar panels to provide backup power during grid outages and maximize the use of solar energy.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:09 pm

REGN

Regeneron Pharmaceuticals (NASDAQ:REGN) announced that long-term outcomes and new analyses of pivotal clinical data for EYLEA HD (aflibercept) Injection 8 mg will be presented at the American Academy of Ophthalmology (AAO) annual meeting. The data includes results from the PULSAR and PHOTON trials in wet age-related macular degeneration and diabetic macular edema. EYLEA HD is being jointly developed by Regeneron and Bayer AG. In the U.S., Regeneron maintains exclusive rights to EYLEA and EYLEA HD.

Portfolio Pulse from Benzinga Newsdesk

November 01, 2023 | 9:05 pm

CYBN

Cybin Inc. (NYSE:CYBN) has shared interim results from its Phase 2 study of psilocybin analog CYB003 on Major Depressive Disorder (MDD). The results showed a significant reduction in depression symptoms three weeks after a single 12mg dose. The company also plans to share topline Phase 1 data for its proprietary deuterated DMT compounds, CYB004 and SPL028, before the end of the year. The stock price rose following the announcement of the interim results.

Portfolio Pulse from Lara Goldstein

November 01, 2023 | 8:51 pm

TSLA

Jim Cramer, host of CNBC's 'Squawk On The Street', has criticized Tesla's Cybertruck, calling it a toy for Elon Musk fans and the ugliest vehicle he's ever seen. He also noted that the recent reduction in production estimates from 250,000 to 200,000 Cybertrucks per year could disappoint Wall Street. Despite his criticisms, Cramer acknowledged that he's optimistic about the Cybertruck's potential and believes Tesla has created an entirely new category of vehicles.

Portfolio Pulse from Adam Eckert

November 01, 2023 | 8:22 pm